We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Handheld Mass Spectrometry Device Detects Cancer by Touch

By HospiMedica International staff writers
Posted on 04 Aug 2023
Print article
Image: The MasSpec Pen was among the 2023 AACC Disruptive Technology Award finalists (Photo courtesy of MS Pen Technologies)
Image: The MasSpec Pen was among the 2023 AACC Disruptive Technology Award finalists (Photo courtesy of MS Pen Technologies)

The existing gold-standard method for diagnosing cancers and delineating the boundary between cancerous and healthy tissue during surgery, known as Frozen Section Analysis, is often slow and occasionally inaccurate. Each sample can take 30 minutes or more for preparation and interpretation by a pathologist, which increases the risk of patient infection and adverse impacts of anesthesia. Furthermore, for certain cancer types, frozen section interpretation can be challenging, leading to unreliable results in about 10 to 20% of cases. Now, a powerful tool rapidly and accurately identifies cancerous tissue during surgery, delivering results in roughly 10 seconds - a speed over 150 times faster than existing technology.

The MasSpec Pen from MS Pen Technologies (Houston, TX, USA) is an innovative handheld device that provides surgeons with precise diagnostic details regarding the specific tissue to be excised or preserved. This aids in enhancing treatment outcomes and minimizing the likelihood of cancer recurrence. Each cancer variant produces a distinctive set of metabolites and other biomarkers that serve as identifiers. The MasSpec Pen extracts and analyzes these metabolites to establish a molecular fingerprint of the tissue. Remarkably, this simple and gentle chemical process enables the MasSpec Pen to rapidly deliver diagnostic molecular data without causing any tissue damage.

The disposable handheld device is easy for physicians to operate. The process involves simply placing the pen against the patient's tissue, initiating the automated analysis via a foot pedal, and waiting a few seconds for the result. The pen releases a droplet of water onto the tissue, into which small molecules migrate. The device then propels the water sample into a mass spectrometer, an instrument that detects thousands of molecules to create a molecular fingerprint. A statistical classifier software instantaneously evaluates the molecular fingerprint obtained from an uncharacterized tissue sample by the MasSpec Pen, utilizing a database of molecular fingerprints collated from 253 human tissue samples. These samples comprised both normal and cancerous tissues from the breast, lung, thyroid, and ovary. Upon completion of the MasSpec Pen analysis, the terms "Normal" or "Cancer" automatically appear on a computer screen. For specific cancers, such as lung cancer, a subtype may also be indicated.

In trials involving tissues extracted from 253 human cancer patients, the MasSpec Pen was able to provide a diagnosis in about 10 seconds, with an accuracy exceeding 96%. The technology could also detect cancer in marginal regions between normal and cancer tissues, which exhibited mixed cellular composition. Additionally, the MasSpec Pen demonstrated its ability to accurately diagnose cancer in live mice with tumors during surgery, without causing any noticeable tissue damage or stress to the animals. The MasSpec Pen shows potential for application as a clinical and intra-operative tool for both ex-vivo and in-vivo cancer diagnosis, and was a finalist for the 2023 AACC Disruptive Technology Award.

Related Links:
MS Pen Technologies

Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Specimen Collection & Transport
Infant Resuscitator
Gold Supplier
Ultrasound System

Print article


Critical Care

view channel
Image: The BASHIR Endovascular Catheter was recently approved by the U.S. FDA (Photo courtesy of THROMBOLEX)

Novel Endovascular Catheter Opens Blocked Arteries Deep Within Lungs

The occlusion of small lung arteries is the main cause of the reduction in blood flow in patients with acute pulmonary embolism. The more occlusions that a patient has, the lower the chances of survival.... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.